Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(5):301-302; doi:10.1093/jnci/djj112
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Hepatitis C Vaccine Approaches Phase II Trial

Caroline McNeil

The first 10% of the full text of this article appears below.

The first prophylactic hepatitis C vaccine to reach human trials could enter phase II testing this year, a landmark for a field that has faced many technical challenges since the virus was identified in 1989. If this vaccine—or one of several other candidates—is successful, the public health impact could be substantial. Hepatitis C is a major cause of liver disease, including hepatocellular carcinoma, a leading cause of cancer deaths worldwide. The vaccines being developed are meant to prevent primary infection with . . . [Full Text of this Article]

Challenges

Other Strategies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?